Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...
The approval of this new label reflects the positive outcome of our ongoing and productive dialogue with the FDA, which shares our commitment to addressing unmet medical ... For more information ...